ThromboGenics reports slowdown of sales of main drug Jetrea

[riky]

ThromboGenics reports slowdown of sales of main drug Jetrea

Belgian biotechnology company ThromboGenics said late on Monday that sales in the United States of its only drug, eye disease treatment Jetrea, had slowed in the second half of 2013. The group has a marketing agreement with Novartis unit Alcon outside the United States but is selling eye drug Jetrea - a treatment for vitreomacular adhesion, an ageing-related condition that can lead to blindness - on its own in the United States. ThromboGenics said it had reorganized its U.S. operations to focus on establishing Jetrea as an earlier treatment for patients with the disorder. It is clear that ThromboGenics is not just introducing a new product.

Source: You are not allowed to view links. Register or Login